Table 1 Characteristics of the genotyped patients
Patients with optimal response at 6 months (n = 32) | Patients with non-optimal response at 6 months (n = 30) | p-value | |
|---|---|---|---|
Age, years, median (range) | 39 (19–66) | 52 (21–71) | 0.0768 |
Gender | 0.5940 | ||
Female, n (%) | 15 (55.6) | 12 (44.4) | |
Male, n (%) | 17 (48.6) | 18 (51.4) | |
Sokal group | |||
Low, n (%) | 21 (65.6) | 4 (13.3)* | |
Intermediate, n (%) | 6 (18.8) | 1 (3.3)* | |
High, n (%) | 5 (15.6) | 2 (6.7)* | |
TKI therapy | |||
First line, n (%) | 29 (90.6) | 30 (100) | |
Imatinib 400 mg, n (%) | 25 (78.1) | 28 (93.3) | |
Imatinib 600 mg, n (%) | 2 (6.7) | ||
Nilotinib 400–600 mg, n (%) | 3 (9.4) | ||
Dasatinib, 100 mg, n (%) | 1 (3.1) | ||
Second line, n (%) | 3 (9.4) | 0 (0) | |
Nilotinib 400–600 mg, n (%) | 1 (3.1)** | ||
Dasatinib, 100 mg, n (%) | 2 (6.3)** | ||